Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03194555 · ClinicalTrials.gov registry record · Phase 2
The Preventive Treatment of Migraine With Low-Dose Naltrexone and Acetaminophen Combination
A Phase 2 study of Migraine With or Without Aura, sponsored by Allodynic Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT03194555 is a Phase 2 study of Migraine With or Without Aura that has completed, run by Allodynic Therapeutics. The registered enrollment target is 12 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03194555, a Phase 2 study of Migraine With or Without Aura, has completed, sponsored by Allodynic Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The Preventive Treatment of Migraine with Low-Dose Naltrexone and Acetaminophen Combination: A Small, Randomized, Double-Blind, and Placebo-Controlled Clinical Trial with an Open-Label Extension for None-Responders
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Low-Dose Naltrexone and Acetaminophen Combination
Study Locations (1)
Florida
- Annette Toledano, M.D. - North Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2017-08-25 |
| Est. Completion | 2018-07-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03194555
The ClinicalTrials.gov registry entry for NCT03194555 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allodynic Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Migraine With or Without Aura appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03194555 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT03194555 about?
NCT03194555 is a clinical study titled "The Preventive Treatment of Migraine With Low-Dose Naltrexone and Acetaminophen Combination". The Preventive Treatment of Migraine with Low-Dose Naltrexone and Acetaminophen Combination: A Small, Randomized, Double-Blind, and Placebo-Controlled Clinical Trial with an Open-Label Extension for None-Responders
What is the current status of trial NCT03194555?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2017-08-25. Estimated completion is 2018-07-28.
What conditions does trial NCT03194555 study?
This clinical trial studies the following conditions: Migraine With or Without Aura.
What interventions are being tested in trial NCT03194555?
The interventions under investigation include: Placebo (DRUG), Low-Dose Naltrexone and Acetaminophen Combination (DRUG).
Who is sponsoring clinical trial NCT03194555?
This trial is sponsored by Allodynic Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03194555 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine With or Without Aura
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.